Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2018 1
2020 6
2021 4
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. Heitzeneder S, et al. Among authors: salzer b. Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34971569 Free PMC article.
Preclinical testing of CAR T cells in zebrafish xenografts.
Grissenberger S, Salzer B, Pascoal S, Wenninger-Weinzierl A, Lehner M, Distel M. Grissenberger S, et al. Among authors: salzer b. Methods Cell Biol. 2022;167:133-147. doi: 10.1016/bs.mcb.2021.07.002. Epub 2021 Aug 20. Methods Cell Biol. 2022. PMID: 35152991
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma.
Worel N, Grabmeier-Pfistershammer K, Kratzer B, Schlager M, Tanzmann A, Rottal A, Körmöczi U, Porpaczy E, Staber PB, Skrabs C, Herkner H, Gudipati V, Huppa JB, Salzer B, Lehner M, Saxenhuber N, Friedberg E, Wohlfarth P, Hopfinger G, Rabitsch W, Simonitsch-Klupp I, Jäger U, Pickl WF. Worel N, et al. Among authors: salzer b. Front Immunol. 2023 Jan 9;13:1004703. doi: 10.3389/fimmu.2022.1004703. eCollection 2022. Front Immunol. 2023. PMID: 36700229 Free PMC article.
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.
Byrgazov K, Anderson C, Salzer B, Bozsaky E, Larsson R, Gullbo J, Lehner M, Lehmann F, Slipicevic A, Kager L, Fryknäs M, Taschner-Mandl S. Byrgazov K, et al. Among authors: salzer b. Ther Adv Med Oncol. 2020 Jul 29;12:1758835920937891. doi: 10.1177/1758835920937891. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32774473 Free PMC article.
An engineering strategy to target activated EGFR with CAR T cells.
Dobersberger M, Sumesgutner D, Zajc CU, Salzer B, Laurent E, Emminger D, Sylvander E, Lehner E, Teufl M, Seigner J, Bobbili MR, Kunert R, Lehner M, Traxlmayr MW. Dobersberger M, et al. Among authors: salzer b. Cell Rep Methods. 2024 Apr 22;4(4):100728. doi: 10.1016/j.crmeth.2024.100728. Epub 2024 Mar 15. Cell Rep Methods. 2024. PMID: 38492569 Free PMC article.
18 results